Skip to content

The Effects of a dietary supplement containing essential amino acids on exercise-induced fatigue, skeletal muscle mass and muscular strength.

The Effects of a dietary supplement containing essential amino acids on exercise-induced fatigue, skeletal muscle mass and muscular strength. - The Effects of a dietary supplement containing essential amino acids on exercise-induced fatigue, skeletal muscle mass and muscular strength.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000050740
Enrollment
60
Registered
2023-03-31
Start date
2023-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Interventions

Ingest 3 packets in total of the test food (essential amino acids containing supplement) each one packet in the morning, in the afternoon, and 30~60 min after their resistance training daily for 10 we

Sponsors

Healthcare Systems Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document 2. Healthy Japanese who are 18 years old or more and under 64 years old 3. BMI of 18.5 kg/m2 or more at the time of informed consent 4. Self-reports participating in resistance training 0.5 to 3 times per week for at least a month prior to the start of intervention. 5. Willing to maintain habitual dietary, lifestyle, and physical activity throughout the study. 6. Willing to refrain from exclusionary medications, supplements, and products throughout the study.

Exclusion criteria

Exclusion criteria: 1.Persons who have chronic illness, receiving medication, have a serious disease history. 2.Hypertension. 3.History or current diagnosis of amino acid metabolism diseases including, but not limited to, Argininosuccinic acidemia, citrullinemia, homocystinuria, maple syrup urine disease, phenylketonuria, and Tyrosinemia type I. 4.Smoker. 5.Experienced pain in chest at rest, during daily activities of living, or when doing physical activity in the last 12 months. 6.Experienced loss of balance because of dizziness or loss of consciousness in the last 12 months. 7.History or presence of a bone, joint, or soft tissue problem that could be made worse by becoming more physically active in the past 12 months. 8.Advised by medical doctor to only perform medically supervised physical activity in the last 12 months. 9.Any known food allergy as well as intolerance or sensitivity to study product ingredients 10.History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer. 11.Major trauma or any other surgical event in the past 90 days. 12.Weight loss or gain >4.5 kg in the past 90 days. 13.Extreme dietary habits or a diagnosed eating disorder. 14.Currently or planning to be on a weight loss regimen during the study. 15.Weight loss medications in the past 90 days. 16.Supplements providing amino acids in the past 30 days. 17.Dietary supplements, or products that are known to affect weight loss, appetite, and satiety in the past 30 days. 18.Female who is pregnant, planning to be pregnant during the study period. 19.Recent history of alcohol or substance abuse in the past 12 months. 20.Persons judged as inappropriate for study participant by the principal investigator 21.Persons who have participated in other tests in the past 1 month, or those who intend to participate in another exam after consenting to the exam.

Design outcomes

Primary

MeasureTime frame
Delayed onset muscle pain Subjective fatigue

Secondary

MeasureTime frame
Muscle strength and endurance Body composition, body mass, body mass index Urinary nitrogen Dietary intake

Countries

Japan

Contacts

Public ContactChihiro Nagayama

Healthcare Systems Co., Ltd. Clinical Research Department

nagayama.chihiro@hc-sys.jp03-6809-2722

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026